4//SEC Filing
ARCH Venture Fund X, L.P. 4
Accession 0000899243-21-005753
CIK 0001770121other
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 7:22 PM ET
Size
42.2 KB
Accession
0000899243-21-005753
Insider Transaction Report
Form 4
ARCH Venture Fund X, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2021-02-08+11,718,750→ 11,718,750 total(indirect: See Footnotes) - Conversion
Series A-2 Convertible Preferred Stock
2021-02-08−5,687,500→ 0 total(indirect: See Footnotes)→ Common Stock (5,687,500 underlying) - Conversion
Common Stock
2021-02-08+11,718,750→ 11,718,750 total(indirect: See Footnotes) - Conversion
Series A-1 Convertible Preferred Stock
2021-02-08−3,687,500→ 0 total(indirect: See Footnotes)→ Common Stock (3,687,500 underlying) - Conversion
Series A-2 Convertible Preferred Stock
2021-02-08−9,375,000→ 0 total(indirect: See Footnotes)→ Common Stock (9,375,000 underlying) - Conversion
Series A-2 Convertible Preferred Stock
2021-02-08−9,375,000→ 0 total(indirect: See Footnotes)→ Common Stock (9,375,000 underlying) - Conversion
Series A-2 Convertible Preferred Stock
2021-02-08−5,687,500→ 0 total(indirect: See Footnotes)→ Common Stock (5,687,500 underlying) - Conversion
Series B Convertible Preferred Stock
2021-02-08−781,250→ 0 total(indirect: See Footnotes)→ Common Stock (781,250 underlying) - Conversion
Common Stock
2021-02-08+10,156,250→ 10,303,750 total(indirect: See Footnotes) - Conversion
Common Stock
2021-02-08+10,156,250→ 10,301,250 total(indirect: See Footnotes) - Conversion
Series A-1 Convertible Preferred Stock
2021-02-08−3,687,500→ 0 total(indirect: See Footnotes)→ Common Stock (3,687,500 underlying) - Conversion
Series B Convertible Preferred Stock
2021-02-08−781,250→ 0 total(indirect: See Footnotes)→ Common Stock (781,250 underlying) - Conversion
Series B Convertible Preferred Stock
2021-02-08−2,343,750→ 0 total(indirect: See Footnotes)→ Common Stock (2,343,750 underlying) - Conversion
Series B Convertible Preferred Stock
2021-02-08−2,343,750→ 0 total(indirect: See Footnotes)→ Common Stock (2,343,750 underlying)
Footnotes (8)
- [F1]The shares of Issuer's Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering.
- [F2]Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
- [F3]Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
- [F4]ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein.
- [F5]Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
- [F6]Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
- [F7]ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
- [F8]The expiration date is not relevant to the conversion of these securities.
Documents
Issuer
Sana Biotechnology, Inc.
CIK 0001770121
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001757011
Filing Metadata
- Form type
- 4
- Filed
- Feb 9, 7:00 PM ET
- Accepted
- Feb 10, 7:22 PM ET
- Size
- 42.2 KB